Not logged in...
About USC Norris
FAQ - Trials
Contact Us - Trials
Support USC Norris
» Contact Us
If you are a patient, please contact
Keck Medical Center of USC
Phase IB Multi-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Anti-Neoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/ß-Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy with FOLFIRINOX (or FOLFOX).
Open to Accrual
Defintions of terms and FAQ about clinical trials.
Heinz Josef Lenz, M.D.
Other Trial Staff:
Ramona Lujan, R.N., Taison Tran, D.M., Arthur Alvarez, D.M., Arthur Alvarez, D.M.
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.